NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

OK so you are saying DCVAX-L is clearly an effective treatment and for those that received an additional dose even more effective. What is the delay lets Fast Track Approval and get this to the patients that need it.

. . . that does is gives the patient a second dose that very likely affects their overall survival (OS). NWBO has repeated stated that that crossover dosing confound the OS data -- that creates significant bias in the trial in the favor of DCVax-L as they get more doses that the SoC control arm . . .